

# Sherko KÃ¼mmel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2086385/publications.pdf>

Version: 2024-02-01

283  
papers

16,200  
citations

28274

55  
h-index

19190

118  
g-index

313  
all docs

313  
docs citations

313  
times ranked

13374  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. <i>Annals of Surgery</i> , 2022, 275, 576-581.	4.2	38
2	A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. <i>Annals of Surgery</i> , 2022, 276, e553-e562.	4.2	95
3	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	7.0	18
4	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBecca trial. <i>European Journal of Cancer</i> , 2022, 162, 45-55.	2.8	12
5	The Search for the Ideal Female Breast: A Nationally Representative United-States-Census Study. <i>Aesthetic Plastic Surgery</i> , 2022, , 1.	0.9	9
6	Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. <i>Journal of Clinical Oncology</i> , 2022, 40, 1903-1915.	1.6	31
7	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 556-567.	27.0	444
8	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. <i>British Journal of Cancer</i> , 2022, 126, 1715-1724.	6.4	14
9	Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline <i>BRCA1/2</i> mutations and high-risk HER-2 negative early breast cancer. <i>Cancer Research</i> , 2022, 82, GS4-09-GS4-09.	0.9	3
10	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. <i>Npj Breast Cancer</i> , 2022, 8, 42.	5.2	9
11	De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR <sup>-</sup> ): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 625-635.	10.7	30
12	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22
13	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2 <sup>-</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	7.0	90
14	Interobserver agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 191-205.	3.0	19
15	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2 <sup>-</sup> Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567.	1.6	49
16	Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer. <i>JAMA Oncology</i> , 2022, , .	7.1	7
17	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. <i>Journal of Clinical Oncology</i> , 2022, 40, 503-503.	1.6	38
18	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	3.7	6

#	ARTICLE	IF	CITATIONS
19	ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer. <i>Modern Pathology</i> , 2022, 35, 1804-1811.	5.5	4
20	Gynecologists' attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 967-980.	1.7	11
21	A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. <i>Breast</i> , 2021, 55, 55-62.	2.2	28
22	Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS) Tj ETQq0 0 0 rgBT /0xerlock 10 Tf 50 61.	1.0	0
23	Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. <i>Cancer Research</i> , 2021, 81, PD2-04-PD2-04.	0.9	20
24	Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. <i>International Journal of Cancer</i> , 2021, 148, 2614-2627.	5.1	5
25	Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 467-476.	2.5	9
26	Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. <i>Breast Cancer Research</i> , 2021, 23, 36.	5.0	7
27	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	10.7	179
28	Effects of an Integrative Mind-Body-Medicine Group Program on Breast Cancer Patients During Chemotherapy: An Observational Study. <i>Current Pharmaceutical Design</i> , 2021, 27, 1112-1120.	1.9	9
29	ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS598-TPS598.	1.6	1
30	LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial. <i>Annals of Oncology</i> , 2021, 32, S48.	1.2	4
31	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. , 2021, 9, e002198.		18
32	Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242). <i>Journal of Clinical Oncology</i> , 2021, 39, 579-579.	1.6	3
33	Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 504-504.	1.6	3
34	The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women's response to integrative breast cancer treatment. <i>BMC Cancer</i> , 2021, 21, 724.	2.6	0
35	Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 363.	2.7	1
36	Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 6537-6566.	1.9	14

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Auricular Acupuncture for the Treatment of Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial. <i>Cancers</i> , 2021, 13, 4082.	3.7	20
38	Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. <i>Annals of Oncology</i> , 2021, 32, 1005-1014.	1.2	63
39	Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. <i>Cancers</i> , 2021, 13, 4564.	3.7	6
40	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4884.	3.7	11
41	123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, S411-S412.	1.2	5
42	VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+ chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. <i>Annals of Oncology</i> , 2021, 32, 1198-1200.	1.2	102
43	The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. <i>Breast</i> , 2021, 59, 58-66.	2.2	4
44	Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). <i>Breast</i> , 2021, 60, 98-110.	2.2	28
45	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 228-235.	1.4	20
46	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 214-227.	1.4	51
47	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1112-1120.	1.8	17
48	Human Acellular Dermal Matrix (Epiflex®) in Immediate Implant-Based Breast Reconstruction after Skin- and Nipple-Sparing Mastectomy and Treatment of Capsular Fibrosis: Results of a Multicenter, Prospective, Observational NOGGO-AWOGyn Study. <i>Breast Care</i> , 2021, 16, 1-7.	1.4	1
49	TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	2.8	14
50	Integrative Onkologie bei gynäkologischen Tumoren. <i>Springer Reference Medizin</i> , 2021, , 1-16.	0.0	0
51	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , 2021, 11, e045239.	1.9	12
52	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. <i>International Journal of Cancer</i> , 2020, 146, 262-271.	5.1	27
53	Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial. <i>Supportive Care in Cancer</i> , 2020, 28, 3605-3615.	2.2	14
54	LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results. <i>Annals of Oncology</i> , 2020, 31, S1146.	1.2	5

#	ARTICLE	IF	CITATIONS
55	The run-in phase of the prospective WSG-ADAPT HR+/HER2+ trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097313.	3.2	18
56	Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant. <i>Npj Breast Cancer</i> , 2020, 6, 31.	5.2	13
57	Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. <i>Cancer</i> , 2020, 126, 4847-4858.	4.1	33
58	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology</i> , The, 2020, 21, e375-e385.	10.7	34
59	357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratumuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, S393.	1.2	5
60	Evidence-based guidelines for managing patients with primary ER+ HER2+ breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020, 6, 21.	5.2	42
61	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 519-530.	10.7	441
62	5. Komplementäre Medizin. , 2020, , 217-240.		0
63	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020, 15, 294-309.	1.4	47
64	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	27.0	1,542
65	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. <i>Annals of Oncology</i> , 2020, 31, 569-581.	1.2	253
66	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1186-1197.	1.6	10
67	Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. <i>Breast</i> , 2020, 50, 11-18.	2.2	3
68	Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study. <i>Cancer Research</i> , 2020, 80, GS3-01-GS3-01.	0.9	3
69	Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. <i>Cancer Research</i> , 2020, 80, GS5-03-GS5-03.	0.9	9
70	Abstract PD1-06: Open label phase 1b/2 study of ladiratumuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. , 2020, , .		28
71	Abstract PD5-10: Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial. , 2020, , .		2
72	MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 506-506.	1.6	44

#	ARTICLE	IF	CITATIONS
73	Abstract P4-10-05: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR- trial. <i>Cancer Research</i> , 2020, 80, P4-10-05-P4-10-05.	0.9	5
74	Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study. , 2020, , .		0
75	Abstract P3-08-40: Prognostic factors associated with clinical outcomes in HR+, HER2- advanced breast cancer: Systematic literature review. , 2020, , .		3
76	Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. , 2020, , .		0
77	Abstract P2-16-05: Efficacy of response- and toxicity-guided neoadjuvant chemotherapy in elderly early breast cancer patients: Results of WSG ADAPT elderly sub-trial. , 2020, , .		0
78	Abstract P1-19-31: RIBECCA - A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole: Results of the third interim analysis. , 2020, , .		0
79	Abstract OT3-14-02: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy - Precycle. , 2020, , .		0
80	Abstract PD5-09: Prognostic and predictive impact of genes and signatures measured with the BC360 panel (Nanostring) in node positive (â%¥pN2a) high risk patients (pts) receiving dose dense (dd) versus standard dosed chemotherapy in an adjuvant randomized trial with a long term follow-up (FU). , 2020, , .		0
81	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019, 26, 3892-3901.	1.5	29
82	Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial. <i>Trials</i> , 2019, 20, 398.	1.6	3
83	Reply to E. HindiÃ© and A.K. Goel et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2705-2707.	1.6	0
84	Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1110-1117.	1.8	2
85	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptorâ€Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	7.1	62
86	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 247-255.	1.4	32
87	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	1.4	72
88	ASCO 2019: New Results in Breast Cancer. <i>Breast Care</i> , 2019, 14, 256-258.	1.4	2
89	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	7.0	76
90	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. <i>BMC Cancer</i> , 2019, 19, 611.	2.6	5

#	ARTICLE	IF	CITATIONS
91	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	2.4	58
92	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69 "GeparSepto. <i>Journal of Clinical Oncology</i> , 2019, 37, 2226-2234.	1.6	95
93	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. <i>Annals of Oncology</i> , 2019, 30, 1279-1288.	1.2	438
94	Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1490-1498.	1.6	16
95	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2114-2121.	5.1	6
96	Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄ„C. <i>Breast Care</i> , 2019, 14, 165-169.	1.4	2
97	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 799-808.	1.6	85
98	Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients. <i>Breast Care</i> , 2019, 14, 159-164.	1.4	2
99	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). <i>Anti-Cancer Drugs</i> , 2019, 30, 394-401.	1.4	3
100	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	2.5	15
101	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto "GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019, 106, 181-192.	2.8	84
102	In-depth gene expression analysis of premenopausal patients with HR+/HER2~ advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1018-1018.	1.6	5
103	RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole "Results of the second interim analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1061-1061.	1.6	0
104	ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS596-TPS596.	1.6	0
105	Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3075-3075.	1.6	0
106	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. <i>Clinical Cancer Research</i> , 2018, 24, 3358-3365.	7.0	11
107	Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 48-53.	1.8	2
108	Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. <i>Journal of the National Cancer Institute</i> , 2018, 110, 628-637.	6.3	88

#	ARTICLE	IF	CITATIONS
109	Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice. <i>Breast Care</i> , 2018, 13, 114-118.	1.4	14
110	Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. <i>Annals of Oncology</i> , 2018, 29, 186-192.	1.2	35
111	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 59-71.	2.5	32
112	Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 179-187.	2.5	8
113	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology</i> , The, 2018, 19, 40-50.	10.7	1,327
114	Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany. <i>Breast</i> , 2018, 37, 89-98.	2.2	21
115	Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Oncotarget</i> , 2018, 9, 15168-15179.	1.8	29
116	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133.	1.6	52
117	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. <i>Breast Care</i> , 2018, 13, 440-446.	1.4	3
118	Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. <i>Annals of Oncology</i> , 2018, 29, viii103.	1.2	3
119	Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). <i>Annals of Oncology</i> , 2018, 29, viii60.	1.2	0
120	Granulomatous Mastitis: A Therapeutic and Diagnostic Challenge. <i>Breast Care</i> , 2018, 13, 413-418.	1.4	97
121	Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?. <i>Cancer Management and Research</i> , 2018, Volume 10, 5423-5431.	1.9	1
122	Jumping Breast Phenomenon Following Subcutaneous Mastectomy: First Description and Grading of a Well-Known Breast Deformity. <i>Breast Care</i> , 2018, 13, 354-358.	1.4	6
123	Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. <i>Annals of Oncology</i> , 2018, 29, 2341-2347.	1.2	203
124	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 904-915.	10.7	648
125	RESPONDER — diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. <i>BMC Cancer</i> , 2018, 18, 851.	2.6	32
126	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 104-104.	1.6	43



#	ARTICLE	IF	CITATIONS
127	Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.. Journal of Clinical Oncology, 2018, 36, 12102-12102.	1.6	2
128	Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).. Journal of Clinical Oncology, 2018, 36, 522-522.	1.6	17
129	Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)â€”An interim safety analysis.. Journal of Clinical Oncology, 2018, 36, 569-569.	1.6	2
130	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS1115-TPS1115.	1.6	3
131	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, TPS602-TPS602.	1.6	30
132	Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.. Journal of Clinical Oncology, 2018, 36, 573-573.	1.6	3
133	Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.. Journal of Clinical Oncology, 2018, 36, 572-572.	1.6	14
134	RIBECCA: A phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozoleâ€”Results of the first interim analysis.. Journal of Clinical Oncology, 2018, 36, 1051-1051.	1.6	0
135	pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy â€” A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast, 2017, 32, 73-78.	2.2	7
136	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Research and Treatment, 2017, 162, 479-488.	2.5	14
137	The effects of yoga and self-esteem on menopausal symptoms and quality of life in breast cancer survivorsâ€”A secondary analysis of a randomized controlled trial. Maturitas, 2017, 105, 95-99.	2.4	15
138	Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy â€” Results from the multi-center SENTINA trial. Breast, 2017, 31, 202-207.	2.2	57
139	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 2017, 82, 237-246.	2.8	38
140	Gynecologic oncologistsâ€™ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. Archives of Gynecology and Obstetrics, 2017, 296, 295-301.	1.7	24
141	Efficacy and safety of nab-paclitaxel 125Âµg/m <sup>2</sup> and nab-paclitaxel 150Âµg/m <sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Research and Treatment, 2017, 163, 495-506.	2.5	20
142	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European Journal of Cancer, 2017, 85, 133-145.	2.8	84
143	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1378.	7.1	300
144	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European Journal of Cancer, 2017, 84, 1-8.	2.8	13

#	ARTICLE	IF	CITATIONS
145	Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. <i>Acta Oncologica</i> , 2017, 56, 1665-1676.	1.8	194
146	Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 573-583.	2.5	149
147	Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. <i>Annals of Oncology</i> , 2017, 28, 497-504.	1.2	75
148	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 165-175.	2.0	22
149	De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR <sup>-</sup> phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. <i>Annals of Oncology</i> , 2017, 28, 2415-2422.	1.2	108
150	De-escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial. Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. <i>Journal of Clinical Oncology</i> , 2017, 35, 3046-3054.	1.6	114
151	Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10068-10068.	1.6	1
152	Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 504-504.	1.6	10
153	A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).. <i>Journal of Clinical Oncology</i> , 2017, 35, 518-518.	1.6	12
154	Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 555-555.	1.6	1
155	Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 571-571.	1.6	8
156	Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 573-573.	1.6	3
157	Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study. <i>Clinical Breast Cancer</i> , 2016, 16, 514-519.	2.4	20
158	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Breast Care</i> , 2016, 11, 315-322.	1.4	6
159	Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature. <i>Breast Care</i> , 2016, 11, 13-20.	1.4	22
160	A Review of Integrative Medicine in Gynaecological Oncology. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 150-155.	1.8	19
161	A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo). <i>Annals of Oncology</i> , 2016, 27, vi67.	1.2	1
162	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2016, 53, 65-74.	2.8	46

#	ARTICLE	IF	CITATIONS
163	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSeptoâ€”GBC 69): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 345-356.	10.7	316
164	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. <i>Journal of Clinical Oncology</i> , 2016, 34, 2341-2349.	1.6	246
165	Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab Å± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 518-518.	1.6	8
166	Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 556-556.	1.6	4
167	Request for complementary and alternative medicine (CAM) in German patients with breast cancer: A cross-sectional survey.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21604-e21604.	1.6	1
168	A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS1096-TPS1096.	1.6	7
169	Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS635-TPS635.	1.6	3
170	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , 2016, 7, 67686-67698.	1.8	50
171	Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-557.	1.6	91
172	Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 529-529.	1.6	0
173	Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin.. <i>Journal of Clinical Oncology</i> , 2016, 34, 581-581.	1.6	7
174	ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS619-TPS619.	1.6	1
175	Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: Results from the prospective multi-center SENTINA trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1054-1054.	1.6	0
176	Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 522-522.	1.6	0
177	Yoga and meditation for menopausal symptoms in breast cancer survivorsâ€”A randomized controlled trial. <i>Cancer</i> , 2015, 121, 2175-2184.	4.1	89
178	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2â€”Positive and Triple-Negative Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 983-991.	1.6	863
179	Hypnosis in Breast Cancer Care. <i>Integrative Cancer Therapies</i> , 2015, 14, 5-15.	2.0	90
180	Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1118-1127.	1.5	77

#	ARTICLE	IF	CITATIONS
181	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 377-387.	2.5	85
182	Using the framework of corporate culture in &ldquo;mergers&rdquo; to support the development of a cultural basis for integrative medicine &ndash; guidance for building an integrative medicine department or service. <i>Patient Preference and Adherence</i> , 2015, 9, 113.	1.8	21
183	Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 1153-1166.	1.7	9
184	Dual Blockade with Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane&ldquo;Anthracycline Containing Chemotherapy&rdquo; DAFNE (GBG-70). <i>Clinical Cancer Research</i> , 2015, 21, 2924-2931.	7.0	38
185	Integrating mindfulness in supportive cancer care: a cohort study on a mindfulness-based day care clinic for cancer survivors. <i>Supportive Care in Cancer</i> , 2015, 23, 2945-2955.	2.2	36
186	Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 710-718.	1.8	16
187	Local and Systemic Therapies for Breast Cancer Patients: Reducing Short-term Symptoms with the Methods of Integrative Medicine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 675-682.	1.8	20
188	Breast Cancer Update 2014 &ldquo; Focus on the Patient and the Tumour. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 170-182.	1.8	9
189	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. <i>British Journal of Cancer</i> , 2015, 113, 1565-1570.	6.4	83
190	Breast cancer therapy planning &ldquo; a novel support concept for a sequential decision making problem. <i>Health Care Management Science</i> , 2015, 18, 389-405.	2.6	3
191	Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial. , 2015, , .		4
192	Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women". , 2015, , .		3
193	Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. <i>Cancer Research</i> , 2015, 75, S2-07-S2-07.	0.9	11
194	Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1004-1004.	1.6	33
195	Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1008.	1.6	21
196	A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1014-1014.	1.6	8
197	Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1032-1032.	1.6	9
198	Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 506-506.	1.6	15

#	ARTICLE	IF	CITATIONS
199	Abstract OT3-2-04: ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer. , 2015, , .		2
200	A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).. Journal of Clinical Oncology, 2015, 33, TPS1101-TPS1101.	1.6	1
201	Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40â€”GeparQuattro). Annals of Oncology, 2014, 25, 81-89.	1.2	54
202	Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer. Breast Cancer: Targets and Therapy, 2014, 6, 115.	1.8	8
203	Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Und Frauenheilkunde, 2014, 74, 1137-1143.	1.8	11
204	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of Oncology, 2014, 25, 1979-1987.	1.2	122
205	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer, 2014, 14, 66.	2.6	19
206	Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Research and Treatment, 2014, 144, 153-162.	2.5	92
207	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncology, The, 2014, 15, 1137-1146.	10.7	382
208	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 747-756.	10.7	810
209	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 510-510.	1.6	6
210	Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.. Journal of Clinical Oncology, 2014, 32, 524-524.	1.6	1
211	A Decision Support Concept for Advanced Treatment Planning for Breast Cancer. Operations Research Proceedings: Papers of the Annual Meeting = Vorträge Der Jahrestagung / DGOR, 2014, , 405-411.	0.1	1
212	Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.. Journal of Clinical Oncology, 2014, 32, e12007-e12007.	1.6	0
213	Metastatic pattern of breast cancer according to immunohistochemical defined subtypes in the transitional phase of adjuvant trastuzumab treatment.. Journal of Clinical Oncology, 2014, 32, e11581-e11581.	1.6	0
214	Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer—results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial. Anticancer Research, 2014, 34, 385-91.	1.1	24
215	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2047-2056.	2.5	28
216	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab â€” Results of the randomised GeparQuinto study (GBG 44). European Journal of Cancer, 2013, 49, 2284-2293.	2.8	75

#	ARTICLE	IF	CITATIONS
217	Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer. <i>Breast Care</i> , 2013, 8, 60-66.	1.4	27
218	Impressions from the San Antonio Breast Cancer Symposium December 2012. <i>Breast Care</i> , 2013, 8, 77-83.	1.4	0
219	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3623-3630.	1.6	302
220	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. <i>Annals of Oncology</i> , 2013, 24, 618-624.	1.2	121
221	Das „Essener Modell“ - ein Konzept zur integrativ-onkologischen Therapie von Brustkrebspatientinnen. <i>Breast Care</i> , 2013, 8, 314-316.	1.4	3
222	Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1138-TPS1138.	1.6	0
223	FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results. <i>Acta Radiologica</i> , 2012, 53, 628-636.	1.1	19
224	Breast Cancer 2012 - New Aspects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 602-615.	1.8	19
225	Advances in Breast Cancer – Looking Back over the Year. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 1117-1129.	1.8	17
226	A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. <i>Annals of Oncology</i> , 2012, 23, 2259-2264.	1.2	34
227	Integrative oncology for breast cancer patients: introduction of an expert-based model. <i>BMC Cancer</i> , 2012, 12, 539.	2.6	38
228	Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell lines. <i>Anticancer Research</i> , 2012, 32, 359-65.	1.1	4
229	Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells. <i>Anticancer Research</i> , 2012, 32, 367-72.	1.1	8
230	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 145-156.	2.5	228
231	Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3791-3797.	1.6	41
232	Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results. <i>British Journal of Radiology</i> , 2011, 84, 126-135.	2.2	27
233	Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. <i>Acta Radiologica</i> , 2011, 52, 1009-1014.	1.1	71
234	First evaluation of the diagnostic accuracy of an automated 3D ultrasound system in a breast screening setting. <i>Anticancer Research</i> , 2011, 31, 2569-74.	1.1	8

#	ARTICLE	IF	CITATIONS
235	High-frequency breast ultrasound for the detection of microcalcifications and associated masses in BI-RADS 4a patients. <i>Anticancer Research</i> , 2011, 31, 2575-81.	1.1	14
236	Prognostic significance of angiogenic factors in uterine cervical cancer. <i>Anticancer Research</i> , 2011, 31, 2589-95.	1.1	19
237	In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer. <i>Anticancer Research</i> , 2011, 31, 2609-15.	1.1	2
238	Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes. <i>Anticancer Research</i> , 2011, 31, 2617-22.	1.1	3
239	The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer. <i>Anticancer Research</i> , 2011, 31, 2645-9.	1.1	4
240	Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. <i>Anticancer Research</i> , 2011, 31, 2651-5.	1.1	18
241	Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1077-1086.	6.4	137
242	Imaging in patients with breast implants—results of the First International Breast (Implant) Conference 2009. <i>Insights Into Imaging</i> , 2010, 1, 93-97.	3.4	16
243	Follow-up of Probably Benign Lesions (BI-RADS 3 category) in Breast MR Imaging. <i>Breast Journal</i> , 2010, 16, 297-304.	1.0	17
244	Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. <i>Annals of Oncology</i> , 2010, 21, 1430-1435.	1.2	16
245	Dynamic Contrast-Enhanced Breast MRI at 7 Tesla Utilizing a Single-loop Coil. <i>Academic Radiology</i> , 2010, 17, 1050-1056.	2.5	30
246	Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. <i>Anticancer Research</i> , 2010, 30, 375-81.	1.1	28
247	Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1543-1550.	6.4	127
248	Reply to the Letter “A different role of FDG PET/CT for axillary lymph node staging in breast cancer”. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1898-1899.	6.4	2
249	Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 401-406.	2.3	12
250	Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. <i>Anticancer Research</i> , 2009, 29, 641-5.	1.1	18
251	Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. <i>Breast Cancer Research</i> , 2008, 10, R77.	5.0	45
252	Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 542-551.	6.3	268

#	ARTICLE	IF	CITATIONS
253	Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study. <i>Journal of the National Cancer Institute</i> , 2008, 100, 552-562.	6.3	231
254	Breast-Conserving Treatment of Breast Cancer – Oncological and Reconstructive Aspects. <i>Gynäkologisch-geburtshilfliche Rundschau</i> , 2008, 48, 56-62.	0.9	21
255	A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. <i>Annals of Oncology</i> , 2008, 19, 871-876.	1.2	42
256	Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1215-1222.	5.0	102
257	Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. <i>Annals of Oncology</i> , 2008, 19, 292-298.	1.2	128
258	Autologous and Alloplastic Breast Reconstruction – Overview of Techniques, Indications and Results. <i>Gynäkologisch-geburtshilfliche Rundschau</i> , 2008, 48, 68-75.	0.9	14
259	10 Jahre Organgruppe Mamma der Nordostdeutschen Gesellschaft für Gynäkologische Onkologie e.V. (NOGGO). <i>Breast Care</i> , 2008, 3, 283-285.	1.4	0
260	Relevance of Dose-Intensity for Adjuvant Treatment of Breast Cancer. , 2008, , 351-360.		0
261	Dose-dense chemotherapy for primary breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 75-81.	2.0	11
262	Real-Time Sonoelastography of the Cervix: Tissue Elasticity of the Normal and Abnormal Cervix. <i>Academic Radiology</i> , 2007, 14, 193-200.	2.5	136
263	Primary Systemic Treatment and Oncoplastic Breast Surgery – Influences and Principles. <i>Breast Care</i> , 2007, 2, 281-286.	1.4	3
264	Partial Mastectomy Reconstruction with Local and Distant Tissue Flaps. <i>Breast Care</i> , 2007, 2, 299-306.	1.4	8
265	Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: Als upfront vs. switching. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 905-916.	2.5	3
266	Real-Time Sonoelastography Performed in Addition to B-Mode Ultrasound and Mammography: Improved Differentiation of Breast Lesions?. <i>Academic Radiology</i> , 2006, 13, 1496-1504.	2.5	121
267	Peripheral Neuroectodermal Tumor (PNET) of the Breast – a 6-Year Follow-Up. <i>Breast Care</i> , 2006, 1, 324-327.	1.4	5
268	Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. <i>British Journal of Cancer</i> , 2006, 94, 1237-1244.	6.4	53
269	Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer – FIGO IIB – bulky. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1159-1167.	0.8	26
270	Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: Feasibility and tolerability in a subset of patients in a randomized trial. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 166-175.	4.4	11



#	ARTICLE	IF	CITATIONS
271	Chemotherapy treatment options for elderly women with breast cancer. <i>Anticancer Research</i> , 2006, 26, 1673-6.	1.1	1
272	Options and limits of surgery after pre-operative chemotherapy in breast cancer. <i>Anticancer Research</i> , 2006, 26, 1677-82.	1.1	9
273	Videodensitometry in the examination of focal breast lesions after injection of an ultrasound contrast agent. <i>Anticancer Research</i> , 2006, 26, 1691-8.	1.1	7
274	Postoperative therapy modalities for cervical carcinoma. <i>Anticancer Research</i> , 2006, 26, 1707-13.	1.1	4
275	Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes. <i>Anticancer Research</i> , 2006, 26, 1719-26.	1.1	10
276	Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report. <i>Anticancer Research</i> , 2006, 26, 1727-31.	1.1	7
277	Epidermal growth factor receptor changes during breast cancer metastasis. <i>Anticancer Research</i> , 2006, 26, 4397-401.	1.1	13
278	Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. <i>Annals of Oncology</i> , 2005, 16, 1624-1631.	1.2	36
279	Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study. <i>Acta Oncologica</i> , 2005, 44, 248-254.	1.8	7
280	Malignant Melanoma Metastatic to the Breast: An Interdisciplinary Challenge. <i>Breast Journal</i> , 2004, 10, 377-379.	1.0	1
281	Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. <i>Breast</i> , 2003, 12, 208-211.	2.2	3
282	Contrast-enhanced MRI of focal liver lesions: Differentiation and detection of primary and secondary liver lesions using resovist-enhanced versus gadolinium-enhanced MRI in the same patient. <i>Academic Radiology</i> , 1998, 5, S75-S79.	2.5	5
283	Magnetic Resonance Imaging of Focal Liver Lesions. <i>Investigative Radiology</i> , 1996, 31, 696-708.	6.2	89